Further characterization of the immune response in mice to inactivated and live rabies vaccines expressing Ebola virus glycoprotein

Vaccine

Volumn 30, Issue 43, 2012, Pages 6136-6141

  Papaneri, Amy B ^a   Wirblich, Christoph ^b   Cooper, Kurt ^a   Jahrling, Peter B ^a   Schnell, Matthias J ^b   Blaney, Joseph E ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Ebola virus; Multivalent; Platform; Rabies virus; T cell; Vaccine

Indexed keywords

BOTULINUM TOXIN A; GAMMA INTERFERON; INACTIVATED RABIES VIRUS GLYCOPROTEIN VACCINE; INACTIVATED VIRUS VACCINE; LIVE VACCINE; RABIES VACCINE; UNCLASSIFIED DRUG; VIRUS GLYCOPROTEIN; VIRUS VECTOR;

ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG FORMULATION; EBOLA VIRUS; FILOVIRUS; HEAVY CHAIN; HUMORAL IMMUNITY; IMMUNIZATION; IMMUNOGENICITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; ANTIBODIES, VIRAL; ANTIBODY SPECIFICITY; EBOLA VACCINES; EBOLAVIRUS; HEMORRHAGIC FEVER, EBOLA; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; INTERFERON-GAMMA; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED BALB C; RABIES VACCINES; T-LYMPHOCYTES; VACCINES, INACTIVATED; VIRAL MATRIX PROTEINS;

EID: 84865718589     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.07.073     Document Type: Article

References (33)

1. Sanchez A., Geisbert T.W., Feldmann H. Filoviridae: Marburg and Ebola viruses. Fields virology 2007, 1409-1448. Lippincott Williams & Wilkins, Philadelphia, PA. 5th ed. D.M. Knipe, P.M. Howley, D.E. Griffin (Eds.).
2. Geisbert T.W., Bausch D.G., Feldmann H. Prospects for immunisation against Marburg and Ebola viruses. Rev Med Virol 2010, 20(November (6)):344-357.
3. Bradfute S.B., Dye J.M., Bavari S. Filovirus vaccines. Hum Vaccine 2011, 7(June (6)):701-711.
4. Bukreyev A.A., Dinapoli J.M., Yang L., Murphy B.R., Collins P.L. Mucosal parainfluenza virus-vectored vaccine against Ebola virus replicates in the respiratory tract of vector-immune monkeys and is immunogenic. Virology 2010, 399(April (2)):290-298.
5. Hensley L.E., Mulangu S., Asiedu C., Johnson J., Honko A.N., Stanley D., et al. Demonstration of cross-protective vaccine immunity against an emerging pathogenic Ebola virus species. PLoS Pathog 2010, 6(May (5)):e1000904.
6. Sun Y., Carrion R., Ye L., Wen Z., Ro Y.T., Brasky K., et al. Protection against lethal challenge by Ebola virus-like particles produced in insect cells. Virology 2009, 383(January (51)):12-21.
7. Warfield K.L., Swenson D.L., Olinger G.G., Kalina W.V., Aman M.J., Bavari S. Ebola virus-like particle-based vaccine protects nonhuman primates against lethal Ebola virus challenge. J Infect Dis 2007, 196(November (Suppl. 2)):S430-S437.
8. Sullivan N.J., Martin J.E., Graham B.S., Nabel G.J. Correlates of protective immunity for Ebola vaccines: implications for regulatory approval by the animal rule. Nat Rev Microbiol 2009, 7(May (5)):393-400.
9. Dye J.M., Herbert A.S., Kuehne A.I., Barth J.F., Muhammad M.A., Zak S.E., et al. Postexposure antibody prophylaxis protects nonhuman primates from filovirus disease. Proc Natl Acad Sci USA 2012, 109(March (13)):5034-5039.
10. Sullivan N.J., Hensley L., Asiedu C., Geisbert T.W., Stanley D., Johnson J., et al. CD8+ cellular immunity mediates rAd5 vaccine protection against Ebola virus infection of nonhuman primates. Nat Med 2011, 17(September (9)):1128-1131.
11. Warfield K.L., Olinger G.G. Protective role of cytotoxic T lymphocytes in filovirus hemorrhagic fever. J Biomed Biotechnol 2011, 2011:984241.
12. Bradfute S.B., Bavari S. Correlates of immunity to filovirus infection. Viruses 2011, 3(July (7)):982-1000.
13. Blaney J.E., Wirblich C., Papaneri A.B., Johnson R.F., Myers C.J., Juelich T.L., et al. Inactivated or live-attenuated bivalent vaccines that confer protection against rabies and Ebola viruses. J Virol 2011, 85(October (20)):10605-10616.
14. Faber M., Lamirande E.W., Roberts A., Rice A.B., Koprowski H., Dietzschold B., et al. A single immunization with a rhabdovirus-based vector expressing severe acute respiratory syndrome coronavirus (SARS-CoV) S protein results in the production of high levels of SARS-CoV-neutralizing antibodies. J Gen Virol 2005, 86(May (Pt 5)):1435-1440.
15. Faul E.J., Aye P.P., Papaneri A.B., Pahar B., McGettigan J.P., Schiro F., et al. Rabies virus-based vaccines elicit neutralizing antibodies, poly-functional CD8+ T cell, and protect rhesus macaques from AIDS-like disease after SIV(mac251) challenge. Vaccine 2009, 28(December (2)):299-308.
16. McGettigan J.P., Pomerantz R.J., Siler C.A., McKenna P.M., Foley H.D., Dietzschold B., et al. Second-generation rabies virus-based vaccine vectors expressing human immunodeficiency virus type 1 gag have greatly reduced pathogenicity but are highly immunogenic. J Virol 2003, 77(January (1)):237-244.
17. Siler C.A., McGettigan J.P., Dietzschold B., Herrine S.K., Dubuisson J., Pomerantz R.J., et al. Live and killed rhabdovirus-based vectors as potential hepatitis C vaccines. Virology 2002, 292(January (1)):24-34.
18. Mustafa W., Al-Saleem F.H., Nasser Z., Olson R.M., Mattis J.A., Simpson L.L., et al. Immunization of mice with the non-toxic HC50 domain of botulinum neurotoxin presented by rabies virus particles induces a strong immune response affording protection against high-dose botulinum neurotoxin challenge. Vaccine 2011, 29(June (28)):4638-4645.
19. Bermejo M., Rodriguez-Teijeiro J.D., Illera G., Barroso A., Vila C., Walsh P.D. Ebola outbreak killed 5000 gorillas. Science 2006, 314(December (5805)):1564.
20. Leroy E.M., Rouquet P., Formenty P., Souquiere S., Kilbourne A., Froment J.M. Multiple Ebola virus transmission events and rapid decline of central African wildlife. Science 2004, 303(January (5656)):387-390.
21. Blasco R., Moss B. Selection of recombinant vaccinia viruses on the basis of plaque formation. Gene 1995, 158(Junuary (92)):157-162.
22. Gomme E.A., Faul E.J., Flomenberg P., McGettigan J.P., Schnell M.J. Characterization of a single-cycle rabies virus-based vaccine vector. J Virol 2010, 84(March (6)):2820-2831.
23. Kuhn J.H., Dodd L.E., Wahl-Jensen V., Radoshitzky S.R., Bavari S., Jahrling P.B. Evaluation of perceived threat differences posed by filovirus variants. Biosecur Bioterror 2011, 9(December (4)):361-371.
24. Bukreyev A., Marzi A., Feldmann F., Zhang L., Yang L., Ward J.M., et al. Chimeric human parainfluenza virus bearing the Ebola virus glycoprotein as the sole surface protein is immunogenic and highly protective against Ebola virus challenge. Virology 2009, 383(January (2)):348-361.
25. DiNapoli J.M., Yang L., Samal S.K., Murphy B.R., Collins P.L., Bukreyev A. Respiratory tract immunization of non-human primates with a newcastle disease virus-vectored vaccine candidate against Ebola virus elicits a neutralizing antibody response. Vaccine 2010, 29(December (1)):17-25.
26. Sullivan N.J., Geisbert T.W., Geisbert J.B., Xu L., Yang Z.Y., Roederer M., et al. Accelerated vaccination for Ebola virus haemorrhagic fever in non-human primates. Nature 2003, 424(August (6949)):681-684.
27. Sullivan N.J., Sanchez A., Rollin P.E., Yang Z.Y., Nabel G.J. Development of a preventive vaccine for Ebola virus infection in primates. Nature 2000, 408(November (6812)):605-609.
28. Warfield K.L., Bosio C.M., Welcher B.C., Deal E.M., Mohamadzadeh M., Schmaljohn A., et al. Ebola virus-like particles protect from lethal Ebola virus infection. Proc Natl Acad Sci USA 2003, 100(December (26)):15889-15894.
29. Jones S.M., Stroher U., Fernando L., Qiu X., Alimonti J., Melito P., et al. Assessment of a vesicular stomatitis virus-based vaccine by use of the mouse model of Ebola virus hemorrhagic fever. J Infect Dis 2007, 196(November (Suppl. 2)):S404-S412.
30. Warfield K.L., Olinger G., Deal E.M., Swenson D.L., Bailey M., Negley D.L., et al. Induction of humoral and CD8+ T cell responses are required for protection against lethal Ebola virus infection. J Immunol 2005, 175(July (2)):1184-1191.
31. Geisbert T.W., Geisbert J.B., Leung A., Daddario-Dicaprio K.M., Hensley L.E., Grolla A., et al. Single injection vaccine protects nonhuman primates against Marburg virus and three species of Ebola virus. J Virol 2009, 83(July (14)):7296-7304.
32. Schnell M.J., McGettigan J.P., Wirblich C., Papaneri A. The cell biology of rabies virus: using stealth to reach the brain. Nat Rev Microbiol 2010, 8(January (1)):51-61.
33. Cleaveland S., Fevre E.M., Kaare M., Coleman P.G. Estimating human rabies mortality in the United Republic of Tanzania from dog bite injuries. Bull World Health Organ 2002, 80(4):304-310.